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Cardiac metastases
with induction chemotherapy, with a poor response. Radio-
therapy was initiated in order to reduce dysphagia. After 
10.8-Gy radiotherapy was stopped because of increasing 
dyspnea arising from the narrowed left major bronchus 
(produced by local progression of the tumor), the place-
ment of a bronchial stent was necessitated. At the same 
time, a second stent was placed in the esophagus to relieve 
the dysphagia. Palliative radiotherapy was given in fi ve 
daily fractions of 4 Gy, with marked alleviation of the 
dysphagia.
In December 2006 he developed atypical chest pain. CT 
of the chest at that time showed regression of the esopha-
geal tumor; but, surprisingly, cardiac metastasis was seen 
(Fig. 2). On echocardiography left ventricular function 
appeared normal. A dense hyperechogenic mass was seen 
in the myocardium, with a small amount of pericardial effu-
sion. Palliative radiotherapy was delivered with anterior-
posterior opposing fi elds. Radiation portals encompassed 
the CM with a margin of 1.5 cm to make sure that, with 
cardiac motion, the target volume remained in the portal. 
In order to shorten the treatment period, we prescribed a 
total dose of 20 Gy, in daily fractions of 4 Gy. Three weeks 
after the initiation of the palliative radiotherapy his symp-
toms were alleviated. Unfortunately we could not confi rm 
this subjective relief with chest CT, because the patient died 
of aspiration pneumonia 10 weeks after the initiation of the 
palliative radiotherapy. No autopsy was performed.
Discussion and review of the literature
Epidemiology
Although cardiac metastases (CM) are much more common 
than primary cardiac tumors, the diagnosis of CM antemor-
tem is seldom made, because more than 90% are clinically 
silent. About 75% of primary cardiac tumors are benign 
and 25% are malignant (4% primary malignancy and 
96% CM). According to the literature, CM have been 
found in 1.5%–20% of autopsies of cancer patients and in 
0.2%–6.5% of subjects in unselected autopsy series.1–11 Most 
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Abstract We report a case of esophageal cancer with symp-
tomatic metastases to the heart; the patient was treated with 
short-course radiotherapy with good symptomatic relief. We 
reviewed the current literature regarding the epidemiology, 
clinical presentation, diagnostic tools, treatment modalities, 
and the prognosis of cardiac metastases. In this report we 
summarize the most recent autopsy studies (published 
between 1975 and 2007), in which we found an autopsy 
incidence of cardiac metastases of 2.3% among the general 
population, while the incidence among autopsies of cancer 
patients was 7.1%. Therefore, we share the opinion with 
others that there has been an increase in the incidence of 
cardiac metastases among cancer patients diagnosed after 
1970, in comparison with the reported incidences in older 
series before 1970 (7.1% vs 3.8%; Kruskal-Wallis rank test; 
P = 0.039). Special attention was given to the role of radio-
therapy in the management of cardiac metastases.
Key words Cardiac metastases · Radiotherapy · Esophageal 
carcinoma
Case report
A 60-year old man presented in January 2006 with carci-
noma of the esophagus (T3N1Mx). A computed tomogra-
phy (CT) scan of the chest at the time of this diagnosis was 
unremarkable regarding the heart (Fig. 1), but the esopha-
geal cancer was well documented. He was initially treated 
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experiences about the incidence of CM were derived from 
postmortem examinations. We summarized the most recent 
autopsy studies (published between 1975 and 2007), and 
found an autopsy incidence of CM of 2.3% among the 
general population, while the incidence among autopsies of 
cancer patients was 7.1% (Table 1). When we compared 
these results to older series published between 1917 and 
195112 (Table 2), we tended to agree with the conclusions 
of Karwinski and Svendsen6 and Lockwood and Broghamer,7 
who suggested an increasing incidence of CM after 1970. 
Therefore, we performed a statistical comparison, using the 
Kruskal-Wallis rank test, and found a statistically signifi cant 
Fig. 1. Chest computed tomography (CT) scan: performed 4 months 
after the diagnosis of esophageal carcinoma, to evaluate the response 
of the esophageal mass to radiation therapy. At that time, the CT scan 
of the heart was unremarkable
Fig. 2. Chest CT scan: performed to evaluate the patient’s complaint 
of atypical chest pain, demonstrating a cardiac mass of 3 × 2.5 cm 
(arrow)
Table 1. Reported incidence of CM in autopsy studies of cancer patients and general populations (published 1975–2007)
Author Year of 
publication
Autopsies; n Malignancies; n (%) CM in cancer 
patients; n (%)
CM in general 
populations (%)
Bussani et al.5 2007 18 751 7 289 (38.9) 662 (9.1) 3.5
Rafajlovski et al.9 2005 11 403 2 928 (25.7) 79 (2.7) 0.7
Abraham et al.2 1999 3 314 806 (24.3) 95 (11.8) 2.9
Silvestri et al.10 1997 4 769 1 928 (40.4) 162 (8.4) 3.4
Mac Gee8 1991 2 455 1 311 (53.4) 57 (4.4) 2.4
Karwinski and Svendsen6 1989 8 571 2 833 (33.0) 130 (4.6) 1.5
Xiong and Smith11 1986 2 050 484 (23.6) 68 (14.0) 3.3
Ambrosio3 1980 2 222 590 (26.5) 38 (6.4) 1.7
Abioye and Maolomo1 1975 6 064 752 (12.4) 64 (8.5) 1.1
Total 59 599 18 921 (31.7) 1 355 (7.1) 2.3
Table 2. Reported incidence of CM in autopsy studies of cancer patients (published 
1917–1951)12







Scott and Garvin 1939 1 082 101 9.3
Burke 1934 327 14 4.3
Pollia and Gogol 1936 1 450 29 2.0
Pirchard 1951 4 375 146 3.3
Ritchie 1941 857 16 1.9
Symmers 1917 298 5 1.7
Willis 1933 323 20 6.2
Total 8 712 331 3.8
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increase in the incidence of CM after 1970 compared to that 
in older series before 1970 (7.1% vs 3.8%; P = 0.039).
With the advent of modern diagnostic tools, better che-
motherapeutic regimens, and better radiation techniques, 
and with the implementation of better perioperative care, 
patients with cancer have a somewhat improved survival. 
With increased longevity, a trend of increased incidence of 
CM has been shown in different studies.5–7 Because of the 
above-mentioned factors, together with the widespread use 
of modern imaging techniques, an increase in the frequency 
of the antemortem diagnosis of CM is to be expected in the 
near future.
Although any malignant tumor can metastasize to the 
heart, the most common tumors with CM potential are car-
cinomas of the lung, pleura, breast, esophagus, and kidney, 
and malignant lymphoma, leukemia, sarcoma, and malig-
nant melanoma.5 In reviewing 32 articles on the epidemiol-
ogy of CM, we found that the combination of bronchogenic 
carcinoma, hematological malignancies, and breast cancer 
accounted for about two-thirds of all tumors with a signifi -
cant tendency for CM. Data on metastatic involvement of 
the heart in childhood are scanty. Data from the available 
literature indicate that more than 90% of CM in childhood 
originate from lymphoma, leukemia, Wilms’ tumor, neuro-
blastoma, hepatoblastoma, and sarcomas.13
Dyspnea, cough, palpitations, syncope, and chest pain are 
the most common presenting symptoms of CM. Sudden 
death may occur secondary to myocardial rupture, ventricu-
lar arrhythmias, or acute myocardial infarction,4,5 The devel-
opment of heart failure, rapid cardiomegaly, arrhythmias, or 
chest pain in a child with history of cancer is very suspicious 
of CM.13
Electrocardiography is nonspecifi c. More than two-thirds 
of patients with CM showed some ECG abnormality. Local-
ized and prolonged ST-segment elevation without Q waves 
appears to be pathognomonic for myocardial tumor inva-
sion.14 Transesophageal and two-dimensional echocardiog-
raphy are considered to be ideal tools for the diagnosis of 
CM. Chest computed tomography (CT) and magnetic reso-
nance imaging (MRI) provide excellent anatomic informa-
tion about CM. Cytological examination of pericardial fl uid 
is of great value for diagnosis in patients with pericardial 
effusion. Defi nite diagnosis requires pathological examina-
tion of tumor tissue obtained by transthoracic or open surgi-
cal biopsy.
Treatment modalities
CM are usually diagnosed in the setting of generalized car-
cinomatosis. At this stage, treatment must be with palliative 
intention, while in rare cases, when the heart is the only site 
of metastasis, treatment could be with curative intention. In 
patients with disseminated disease, radiotherapy should be 
attempted to relieve troublesome symptoms, to produce 
local control, and to stabilize hemodynamic disturbance. In 
such patients with limited life expectancy and poor perfor-
mance status, it is very important to keep the treatment 
time as short as possible. Short-course radiotherapy may be 
suitable to achieve these objectives. In chemosensitive 
tumors, such as leukemias, lymphomas, and germ cell 
tumors, chemotherapy is recommended. If technically fea-
sible, resection of CM, in highly selected patients, offers the 
best chance of prolonged survival, although the periopera-
tive mortality rate remains high (40%). Because patients 
suitable for surgery generally have a better prognosis than 
inoperable patients, postoperative chemotherapy and/or 
radiotherapy should be given to reduce the chance of local 
recurrence.15
The role of radiotherapy
The concept of using radiation therapy to treat CM is almost 
as old as the technique itself. One of the earliest case reports 
was that by Shelburne and Aronson,16 published in 1940, 
followed by another early report, by Blotner and Sosman,17 
in 1944. Nowadays more is known about the tolerance of 
the heart to radiation therapy. Emami et al.18 reported 
information about the [tolerance dose (TD)] 5/5 (the prob-
ability of a 5% incidence of radiation-induced heart com-
plications within 5 years from treatment) and the TD 50/5 
(the probability of a 50% incidence of complications within 
5 years from treatment) for partial and whole-organ toler-
ance to radiotherapy. Depending on these data, we assume 
that, in radiosensitive tumors such as lymphomas, CM could 
be controlled with a radiation dose as low as 20 Gy, while 
less radiosensitive tumors would require a higher radiation 
dose to produce the same improvement rates (35–50 Gy). 
In general, a total dose of 45 Gy, in 25 fractions of 1.8 Gy, 
would be appropriate in a curative setting; an additional 
dose of 10–15 Gy may be delivered through small portals, 
when indicated.19
Management of malignant pericardial effusion
Malignant pericardial effusion or tamponade is an acute 
life-threatening oncological complication requiring emer-
gency pericardiotomy. A median survival of 4 months had 
been reported in this group of patients.4,5 Symptomatic 
malignant pericardial effusion requires repeated pericardi-
ocentesis, possibly with a laparoscopic technique.20 However, 
if this procedure fails percutaneous balloon pericardios-
tomy can be considered. Today, more invasive procedures 
are only rarely performed in very ill patients.21 Radiation 
therapy did prolong life in patients with pericardial effusion 
as compared with repeated pericardiocentesis alone.22 Instil-
lation of tetracyclines as sclerosing agents has been a useful 
palliative procedure.23 Instillation of radioactive phospho-
rus has also been shown to be effective, but the technical 
expenditure is high.24 Instillation of different chemothera-
peutic agents (especially cisplatin) has also been success-
fully applied to prevent recurrent effusion.25
In the treatment of CM in childhood, early operation 
should be considered only in patients with decompensated 
hemodynamics, because of the high perioperative mortality. 




It seems that whatever the treatment selected, the clinical 
evolution is usually disappointing, and patients with CM die 
within a year of the diagnosis, on average. Occasional 
patients have survived for several years. Overall, a 5-year 
survival rate of only 7% has been reported. This poor prog-
nosis makes it important to select the appropriate mode of 
therapy, probably with a rather restrictive approach to the 
use of heart surgery in this situation.20,21
Conclusion
Surgical resection of CM is the treatment of choice in highly 
selected patients with a long life expectancy and a good 
performance status. Radiation therapy should be used as 
palliative therapy for inoperable and/or nonresectable, as 
well as for chemoresistant CM. We recommend the use of 
a short-course hypofractionated schedule in patients with a 
poor predicted survival, as in our patient, as this is more 
convenient for the patient and more cost effective. After 
reviewing the most recent literature available, we share the 
opinion, with other investigators, that there has been an 
increase in the incidence of CM after 1970 compared with 
that in older series before 1970 (P = 0.039). From the most 
recent articles collected, we found an average incidence of 
CM of 2.3% among autopsies of general populations and 
an average incidence of CM of 7.1% among autopsies of 
cancer patients.
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